Similarly, MERTK overexpression was sufficient to confer erlotinib resistance in a mtEGFR-expressing NSCLC cell line and treatment with a MERTK-selective inhibitor re-sensitized the cells to erlotinib [55]. Here, MERTK is linked to non-small cell lung carcinoma.